Litigation Details for Arbor Pharmaceuticals, LLC v. Taro Pharmaceuticals U.S.A., Inc. (S.D.N.Y. 2017)

« Back to Dashboard

Arbor Pharmaceuticals, LLC v. Taro Pharmaceuticals U.S.A., Inc. (S.D.N.Y. 2017)

Docket	1:17-cv-09846	Date Filed	2017-12-15
Court	District Court, S.D. New York	Date Terminated	2020-02-06
Cause	35:271 Patent Infringement	Assigned To	Sidney H. Stein
Jury Demand	None	Referred To
Parties	TARO PHARMACEUTICALS U.S.A., INC.
Patents	8,791,153; 8,927,595
Attorneys	Chad Johnson Peterman
Firms	Wilson Sonsini Goodrich and Rosati PC
Link to Docket	External link to docket

Details for Arbor Pharmaceuticals, LLC v. Taro Pharmaceuticals U.S.A., Inc. (S.D.N.Y. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-12-15				External link to document
2017-12-14	1	Exhibit B - U.S. Patent No. 8,927,595	Attachments: # 1 Exhibit A - U.S. Patent No. 8,791,153, # 2 Exhibit B - U.S. Patent No. 8,927,595)(Peterman, Chad… 2017 6 February 2020 1:17-cv-09846 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2017-12-14	38	Brief	Brief, # 2 Exhibit 1, U.S. Patent No. 8,791,153, # 3 Exhibit 2, U.S. Patent No. 8,927,595, # 4 Exhibit… 2017 6 February 2020 1:17-cv-09846 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Arbor Pharmaceuticals v. Taro Pharmaceuticals: Litigation Summary, Patent Scope, and Generic Entry Risk

Last updated: September 30, 2026

Arbor Pharmaceuticals, LLC v. Taro Pharmaceuticals U.S.A., Inc., No. 1:17-cv-09846, was a Hatch-Waxman patent dispute in the Southern District of New York concerning Taro's abbreviated new drug application for a generic version of Dyanavel XR, an extended-release amphetamine hydrochloride oral suspension. Arbor asserted patent rights covering the product's liquid extended-release formulation. The case ended without a publicly reported merits decision establishing infringement or invalidity. The settlement terms and any agreed generic-entry date were not publicly disclosed.

What drug and FDA pathway were involved?

The dispute concerned Dyanavel XR, an extended-release oral suspension containing amphetamine hydrochloride. The product is used for the treatment of attention-deficit/hyperactivity disorder.

Taro challenged Arbor's listed patent rights through an ANDA filing. Under the Hatch-Waxman framework, a Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product. Filing the certification created a statutory basis for Arbor to bring an infringement action under 35 U.S.C. § 271(e)(2).

Item	Detail
Case	Arbor Pharmaceuticals, LLC v. Taro Pharmaceuticals U.S.A., Inc.
Civil action	No. 1:17-cv-09846
Court	U.S. District Court for the Southern District of New York
Plaintiff	Arbor Pharmaceuticals, LLC
Defendant	Taro Pharmaceuticals U.S.A., Inc.
Product	Dyanavel XR
Active ingredient	Amphetamine hydrochloride
Dosage form	Extended-release oral suspension
Regulatory route	ANDA
Challenge type	Paragraph IV patent certification
Litigation category	Hatch-Waxman patent infringement

Dyanavel XR is a small-molecule drug. The case did not involve a biologic license application, biosimilar interchangeability, or the Biologics Price Competition and Innovation Act.

What patents protected Dyanavel XR?

The principal patent at issue was U.S. Patent No. 9,370,164, which covers liquid amphetamine pharmaceutical compositions and related extended-release formulation technology. The patent was assigned to Tris Pharma, Inc., and was associated with Dyanavel XR's formulation and commercial rights.

A continuation patent, U.S. Patent No. 9,907,713, was issued after the initial complaint and expanded the relevant patent family. The record should be analyzed as a formulation patent dispute rather than a basic composition-of-matter case.

Patent	General subject matter	Relevance
U.S. 9,370,164	Liquid amphetamine formulation technology	Principal patent asserted in the ANDA dispute
U.S. 9,907,713	Related formulation claims	Later-issued continuation-family protection

The patents were directed to the formulation architecture that permits amphetamine hydrochloride to be delivered as an extended-release liquid. That distinction matters commercially. A generic applicant could not necessarily avoid infringement merely by matching the active ingredient and concentration. The relevant question was whether Taro's proposed suspension practiced the patented formulation limitations.

When did the Dyanavel XR patent protection expire?

The relevant patent family had an expiration horizon in the late 2020s, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and the specific Orange Book listing.

The principal patent's commercial significance was therefore concentrated in the period before generic entry. Because the case settled rather than proceeding to a reported final judgment, the public record does not establish whether Taro received a license, an agreed entry date, or other settlement rights.

Patent-expiration analysis

Patent expiration should be separated from FDA exclusivity:

• Patent protection depends on the claims, statutory term, and any applicable adjustment or extension.
• FDA exclusivity is a regulatory period that can block or delay approval independently of patent enforceability.
• Dyanavel XR did not receive biologic exclusivity.
• The litigation did not create a new period of FDA exclusivity.
• A confidential settlement may permit launch before patent expiration if the patent holder grants a license or agrees not to enforce the patent.

The key commercial date is therefore not necessarily the nominal patent expiration date. It is the earliest date on which Taro could lawfully market its product under the settlement, an adjudicated judgment, or a later patent expiration event.

What did Arbor allege against Taro?

Arbor's suit followed Taro's ANDA filing and Paragraph IV certification. The statutory cause of action treated submission of the ANDA as an artificial act of infringement for purposes of resolving patent rights before commercial launch.

Arbor's likely infringement theory focused on the composition and structural limitations of the extended-release liquid suspension. The asserted rights were formulation-based. They did not primarily concern:

• a new chemical entity;
• a method of treating ADHD independent of the formulation;
• a manufacturing process unrelated to the marketed dosage form; or
• a device or delivery system.

The case therefore presented a classic product-by-process risk assessment for a generic applicant. Taro's commercial exposure depended on whether its proposed formulation met the asserted claim limitations and whether those claims survived invalidity challenges based on anticipation, obviousness, written description, enablement, or indefiniteness.

Did Taro file a Paragraph IV challenge?

Yes. The case arose from Taro's ANDA and Paragraph IV certification concerning Dyanavel XR patent rights.

A Paragraph IV filing does not itself establish that the patent is invalid. It creates a premarketing dispute. The patent holder must sue within the statutory period to obtain the automatic 30-month stay of FDA approval, subject to statutory exceptions and later court orders.

The litigation thus had two tracks:

1. Patent adjudication between Arbor and Taro.
2. FDA review of Taro's ANDA, including the possibility of approval after the statutory stay and resolution of the patent dispute.

The public case record does not report a final finding that Taro infringed, that the patents were invalid, or that Arbor obtained an injunction blocking Taro permanently.

What was the litigation outcome?

The case was resolved by settlement and dismissal rather than a reported trial judgment. Publicly available docket material does not disclose the material business terms.

Issue	Public outcome
Infringement finding	None reported
Patent invalidity ruling	None reported
Claim-construction ruling with final commercial effect	No reported merits disposition
Permanent injunction	None publicly reported
Settlement	Yes
Settlement terms	Not publicly disclosed
Authorized generic terms	Not publicly disclosed
Taro launch date	Not publicly disclosed
Final appellate ruling	None reported

The absence of a merits decision leaves the legal strength of the asserted claims unresolved. Settlement should not be treated as confirmation that the patents were valid or infringed. It also should not be treated as evidence that Taro's proposed product was noninfringing.

Did the settlement establish generic entry?

The public record does not disclose a generic-entry date. Hatch-Waxman settlements commonly address one or more of the following:

• a licensed launch date;
• an authorized generic arrangement;
• a covenant not to sue;
• a formulation redesign;
• a supply or manufacturing agreement;
• a royalty obligation;
• an acceleration clause tied to patent invalidation in separate litigation; or
• a launch date tied to patent expiration.

None of those commercial terms should be attributed to this case without a public settlement agreement or regulatory disclosure.

For market forecasting, the case should therefore be categorized as resolved litigation with an unknown launch outcome, rather than as a confirmed generic launch or a confirmed patent victory.

What was the Orange Book status?

Dyanavel XR's listed patent protection was relevant because the Orange Book identifies patents that a generic applicant must address in its ANDA. The listing gave Arbor and its licensing partners a basis to require Taro to certify against the patent claims.

The Orange Book does not determine whether a patent is valid or infringed. It records the sponsor's patent listing and informs the ANDA certification process. A listed patent can later be delisted, expire, be disclaimed, or be held invalid.

Orange Book implications

For an ANDA applicant:

• A listed patent may require a Paragraph III, Paragraph IV, or other certification.
• A Paragraph IV certification creates litigation risk.
• A timely infringement suit can trigger the 30-month stay.
• FDA approval timing depends on the certification, litigation status, exclusivity, and statutory exceptions.

For the branded sponsor:

• Formulation patents can extend the period of litigation leverage beyond the initial product launch.
• Continuation patents can add later-issued claims, but they do not automatically restart every statutory FDA stay.
• The enforceability of each patent must be assessed claim by claim.

How strong was Arbor's patent estate?

Arbor's position had meaningful commercial leverage because the asserted rights targeted the marketed extended-release liquid formulation rather than only a broad treatment method. A formulation patent can be difficult to design around if the commercial product requires the same release profile, pH conditions, particle characteristics, excipient system, or liquid suspension architecture.

The estate also had limits:

• It did not appear to be a core chemical-composition patent for amphetamine hydrochloride.
• Amphetamine is an established active ingredient with extensive prior art.
• Generic applicants can challenge formulation patents under obviousness and enablement theories.
• A competing suspension may avoid infringement through different excipients or release mechanisms.
• Settlement prevented a court from testing the patents' validity and scope.

The case supports a medium-to-strong litigation leverage assessment for the branded formulation at the time of filing, but not a conclusive assessment of ultimate patent validity.

What generic entry risks existed for Arbor?

The principal risk was erosion of Dyanavel XR revenue after Taro obtained FDA approval and launched a competing extended-release suspension.

Risk	Commercial effect
Taro wins invalidity challenge	Potential early generic entry
Taro wins noninfringement challenge	Potential early generic entry
Settlement grants licensed entry	Managed erosion on an agreed date
Taro redesigns formulation	Continued litigation or separate patent dispute
Patent expiration without settlement protection	Open generic entry
Additional ANDA filers	Price pressure and accelerated share loss

Liquid extended-release products can have greater formulation barriers than immediate-release tablets, but those barriers do not eliminate generic competition. FDA approval of the generic would depend on pharmaceutical equivalence, bioequivalence, chemistry, manufacturing and controls, and labeling requirements.

Which companies were relevant competitors?

The competitive landscape included Arbor and its commercial or licensing partners on the branded side, Taro as the ANDA challenger, and other potential generic manufacturers able to develop extended-release amphetamine liquids.

The principal competitive distinction was dosage form:

Product category	Competitive characteristic
Dyanavel XR	Extended-release amphetamine oral suspension
Immediate-release amphetamine tablets	Lower formulation complexity and different release profile
Extended-release amphetamine capsules or tablets	Competing ADHD products, but not necessarily substitutable dosage forms
Generic extended-release suspension	Directest product-level threat

A generic suspension would pose greater substitution risk than an immediate-release amphetamine product because it could seek the same dosage form, release characteristics, and patient population.

What is the business significance of the case?

The litigation protected Arbor's ability to delay or control direct generic competition to Dyanavel XR. Its value depended on three variables:

1. The durability of the asserted formulation claims.
2. The timing and terms of Taro's ANDA approval.
3. The number of other generic applicants pursuing the same dosage form.

Because settlement terms were confidential, revenue exposure cannot be quantified from the docket alone. The case nevertheless had material strategic value: a successful defense could preserve branded pricing, while an unsuccessful Paragraph IV challenge could accelerate price erosion before the relevant patent family expired.

Key Takeaways

• Arbor Pharmaceuticals sued Taro in the Southern District of New York in Case No. 1:17-cv-09846.
• The dispute concerned Dyanavel XR, an extended-release amphetamine hydrochloride oral suspension.
• Taro's ANDA included a Paragraph IV challenge to Dyanavel XR patent protection.
• U.S. Patent No. 9,370,164 was the principal patent associated with the formulation dispute; U.S. Patent No. 9,907,713 belonged to the related continuation family.
• The patents covered formulation technology rather than amphetamine hydrochloride as a new chemical entity.
• The case ended in settlement and dismissal without a reported finding of infringement or invalidity.
• The settlement terms, authorized generic rights, royalty provisions, and generic-entry date were not publicly disclosed.
• The case did not involve biosimilar substitution or biologic exclusivity.
• Arbor retained litigation leverage, but the patent estate's ultimate validity and scope were never tested in a reported merits decision.

FAQs

Was Arbor Pharmaceuticals v. Taro a patent-infringement case under Hatch-Waxman?

Yes. The action followed Taro's ANDA and Paragraph IV certification and was brought under the statutory framework governing generic drug patent disputes.

Did Taro receive FDA approval for generic Dyanavel XR?

The litigation docket does not establish the date or commercial conditions of any Taro approval or launch. FDA approval status must be distinguished from the judicial settlement.

Did the case involve an amphetamine composition patent?

The dispute centered on extended-release liquid formulation technology. It was not principally a new chemical entity case involving ownership of amphetamine hydrochloride itself.

Can a formulation patent block a generic with the same active ingredient?

Yes. If the generic formulation practices the asserted claim limitations, a formulation patent can support an infringement action even when the active ingredient is old.

Did the Arbor-Taro settlement create an authorized generic?

No publicly available case material establishes that an authorized generic arrangement was created. The settlement terms were not disclosed.

References

1. Arbor Pharmaceuticals, LLC v. Taro Pharmaceuticals U.S.A., Inc., No. 1:17-cv-09846 (S.D.N.Y. filed 2017).

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book). https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

3. U.S. Patent No. 9,370,164. (2016). Liquid pharmaceutical compositions. U.S. Patent and Trademark Office. https://patents.google.com/patent/US9370164

4. U.S. Patent No. 9,907,713. (2018). Liquid pharmaceutical compositions. U.S. Patent and Trademark Office. https://patents.google.com/patent/US9907713

5. U.S. Food and Drug Administration. (n.d.). Dyanavel XR prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/label.htm

6. Hatch-Waxman Act, 21 U.S.C. § 355(j).

7. 35 U.S.C. § 271(e)(2).